Overview

A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)

Status:
Completed

Trial end date:
2018-01-01

Target enrollment:

Participant gender:

Summary

A phase II trial to assess the activity and safety of PD0332991 in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET) with overexpression of cell cycle markers (Cdk4 and/or phospho-Rb1 and/or cyclin D1)

Phase:

Phase 2

Details

Lead Sponsor:

Grupo Espanol de Tumores Neuroendocrinos

Treatments:

Palbociclib